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Introduction: Alloimmunization to red blood cell antigens is one of the 
main complications of transfusion therapy. The appropriate pre-transfusion 
tests are necessary in order to minimize hemolytic reactions related to RBC 
alloantibodies. The aim of this study was to determine the frequency and 
specificity of RBC alloantibodies detected during pre-transfusion tests in 
addition to risk factors of alloimmunization in the hospitalized population 
in Tehran, Iran.   
Materials and Methods: In this retrospective study, the characteristics and 
type of alloantibodies in 31 alloimminized patients among 6029 
hospitalized patients of Imam Khomeini general hospital were examined 
during September 2016 to January 2017. 
Results: The RBC alloantibody prevalence was 0.5% with the male: 
female ratio of 1:5.2. The most frequent antibodies were anti-D (30%), 
anti-E (24%) and anti-K (12%). Female sex, age, history of transfusion and 
pregnancy or abortion history were associated with alloimmunization.  
Conclusion:The alloimmunization rate were relatively low in hospitalized 
patients in this study. Female sex, age, history of transfusion and 
pregnancy sound to be the risk factors of alloimmnization. 
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     Nowadays, blood transfusion has 
become a major part of healthcare system 
and alloimmunization is an important 
adverse effect for those patients undergoing 
blood transfusion. The alloantibodies are 
the main causes of immediate and delayed 
hemolytic transfusion reactions (HTRs).  
Frequency of blood group alloantibodies 
has been reported differently in various 
study populations including hospital-based 
patients, blood donors and patients with 
hematologic disorders. Red Blood Cell 
alloantibodies have been reported in up to 
0.8 percent of blood donors and 
approximately 1-2 percent of hospital-based 
patients [1-4]. The higher rate of about 5 to 
30 percent has been reported in transfused-
dependent patients [5, 6]. The wider rates 
were detected in those with 
hemoglobinopathies (3-76%) [7-10]. It has 
been reported that alloimmunization rate in 
children with sickle cell is as high as 29% 
while in adults, the rate  is 47% [11-13]. 
Red blood cell alloimmunization results 
from multiple risk factors, including sex, 
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history of blood transfusion, pregnancy, 
racial differences between transfusion 
recipients and blood donor and the number 
of transfusion as well as the age of onset, or 
antigen disparity between mother and fetus. 
Due to the importance of alloimmunization 
in patients, particularly pregnant females, 
and to avoid the technical and official faults 
of cross-match tests, antibody screening test 
should be carried out properly and the 
records must be kept and transferred with 
the patients. 
During pre-transfusion testing, the patient’s 
blood is screened for alloantibodies. Here, 
unreliable pre-transfusion tests and 
inappropriate methods to identify 
alloantibodies are the main reasons of 
missing immunized patients. Time courses 
of antibody induction (usually at least one 
month up to four months after first 
transfusion) could be considered as one of 
the most important factors affecting 
antibody screening, so testing too early or 
too late could lead to failure of antibody 
screening [14, 15]. Due to the serious 
consequences of undetected alloantibodies, 
performing appropriate pre-transfusion tests 
seems quite crucial. On the other hand, a 
truthful antibody screening test with the 
purpose of omitting cross match test is very 
important as to avoid unnecessary packed 
cell reservation and saving blood sources. 
While extended red blood cell phenotyping 
for all donors and patients is not affordable 
in developing countries like Iran, type and 
screen tests before transfusion must be 
sensitive and reliable enough to avoid 
alloimmunization. This retrospective study 
was set out to review the frequency and 
specificity of clinically significant RBC 
alloantibodies in our hospital blood bank 
records to evaluate how pre-transfusion 
tests could have impact on 
alloimmunization. 
 
2. Materials and Methods 
2.1 Subjects Studied 
     In this study, records on Red blood cell 
clinically significant alloantibodies in blood 
bank database of Imam Khomeini hospital, 
the referral center and the biggest multi-
disciplinary general teaching hospital in 
Iran with 1300 active bed were examined 
retrospectively. The total of 6029 
hospitalized patients (3984 female and 2045 
male) in Imam Khomeini hospital of Tehran 
were retrieved for analysis from September 
2016 to January 2017. An extended red cell 
antigen panel was performed to detect 
alloantibodies. For alloimmunized patient, 
demographic characteristics including sex, 
age, medical history, transfusion history, 
pregnancy history and abortion history were 
collected from hospital medical records. 
Records with missing data were excluded. 
In order to ensure that the same patients 
were not included in the study repeatedly, in 
case a patient had multiple screening results 
during the hospitalized period, the record 
would be entered into database only once. 
Clinical characteristics which were studied 
were the underlying disease, previous 
transfusion and the reason for transfusion, 
pregnancy and abortion history. 
Transfusion-dependent patients were 
excluded from this study. 
  
2.2 Serological testing 
     Pre-transfusion tests were carried out for 
all the patients who applied for blood 
transfusion in the hospital. Pre-transfusion 
testing included ABO group and Rh-D type, 
antibody screening and compatibility 
testing. Antibody screening was performed 
by testing a patient’s plasma against a 
reagent of O red blood cell. Albumin was 
used to enhance the antigen antibody 
reactions. When the alloantibody screening 
was positive, patient’s plasma was 
examined over again for alloantibody with 
commercial 3-cell panel of reagent O RBCs, 
including the RBC’s frequent antigens such 
as Rh, KELL, Duffy, Kidd, Lewis, MNS, P 
and Lutheran blood group system 
(Immunohematology reference laboratory 
of the Iranian Blood Transfusion 
Organization in Tehran, Iran, Lot N: 
16IP3C105). In those samples with positive 
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antibody screening test, antibody 
identifications were done with 11-cell 
panel, covering the US Food and 
Administration-recommended RBC 
antigens in LISS (DiaLISS, Bio-Rad) with 
and without papain. Antibody screenings 
were also done with the commercial anti-
globulin gel card (Invitrogel AHG 
Coombs). The criteria for antibody 
specificity were based on American 
Association of Blood Banks. 
 
2.3 Statistical analysis 
     Analyses and data management were 
performed using statistical software SPSS 
version 23.0 and Excel 2016, Microsoft 
Corporation. Continuous variables with 
were compared with a t-test. Comparison of 
categorical variables was carried out, using 
chi-square test or Fisher's exact test. P 




     After excluding multi-transfused 
patients, such as hemophilia, thalassemia, 
and leukemia from the present study, the 
total data from 6029 hospitalized patients 
(2047 males and 3982 females) with the age 
of 1 year to 90 years were analyzed. 
Totally, 50 clinically significant 
alloantibodies were found in 31 patients, 
demonstrating the alloantibody prevalence 
of 0.5 percent in this study. Out of the 31 
patients with alloantibodies, 20 (64.5%) had 
single antibody, whereas the remaining 11 
patients (35.4%) had multiple 
alloantibodies, 5 patients had two 
antibodies, 4 patients had three antibodies 
and 2 patients had more than three 
antibodies). Among patients with single 
antibody, those with anti-D were the most 
(50%) and among the patients with multiple 
antibodies, the combination of anti-D and 
anti-C had the highest ratio. Overall, the 
most coexisting alloantibodies were seen in 
Rh system antibodies. The 8 frequently 
identified alloantibodies were the anti-D 15 
of 50 (30%), anti-E 12 of 50 (24%), anti-K 
6 of 50 (12%), anti-C 5 of 50 (10%), anti-c 
4 of 50 (8%), anti-e 4 of 50 (8%), anti-jk 
b 
2 
of 50 (4%) and anti-s 2 of 50 (4%). 
Antibody specificity and frequency in 31 




Table 1. Frequency and specificity of alloantibodies in the alloimmunized patients* 
Type of alloantibody n =50 (%) 
Anti-D 15 (30) 
Anti-E 12 (24) 
Anti-K 6 (12) 
Anti-C 5 (10) 
Anti-c 4 (8) 
Anti-e 4 (8) 
Anti-jk
b
 2 (4) 
Anti-s 2 (4) 
 
Of all alloimmunized patients, 28 patients 
(90.3%) had the history of transfusion and 3 
patients had no transfusion history. In 26 
alloimmunized females, 23 patients (88.4%) 
had history of pregnancy or abortions. The 
alloimmunized patients were categorized 
according to age, sex, transfusion history 
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Table2. Demographic characteristics of immunized and non-immunized patients 
 
These data were collected in order to find 
out if there would be any relations between 
these factors and alloimmunization. Among 
31 alloimmunized patients, 26 were 
females. Females registered the higher rates 
of alloantibody formation (83.8%), in 
comparison to males (16.1%) (Particularly 
anti-D).  This is possibly because of more 
exposure to immunizing events through 
pregnancy. Overall, the male: female ratio 
of alloimmunization was 1:5.2 (5 males, 26 
females). The most clinically significant 
alloantibodies in females with positive 
screening test were anti-D and anti-E, 
respectively. In male, anti-K was the most 
prevalent antibody. Alloimmunized patients 
were between 6-78 years of age. 
Interestingly, the prevalence of alloantibody 
detection was significantly different 
between various age groups. The highest 
frequency was identified in patients aged 
21-30 years and among the other patients, 
the higher rate of alloimmunization was 
seen in patients between 31-40 years old. 




Figure 1. Alloimmunization between different age groups 
 
4. Discussion 
     In this multi-variant retrospective study, 
the frequency of clinically significant 
alloantibodies in hospitalized patientsm and  
 
the factors influencing incidence of 
alloimmunization were investigated. Age, 
sex, transfusion history and pregnancy 







Mean age in years 
(median; range) 
38.77 (34; 6-78)        40.0 (37; 1-90)             <0.05 




3958   
 Male 5 2040   
Pregnancy/abortion  
             23 199  <0.001    
Transfusion History 
 
28 429  <0.001    
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and were the indicators of alloimmunization 
against red blood cell antigens. 
The alloimmunization rate in hospitalized 
patients of the present study was 0.5%. In 
two other previous studies in Iran on 
transfusion-independent patients 
undergoing elective surgery, the prevalence 
of alloantibodies were 1% and 0.92% [1, 3]. 
This study’s results also revealed the lower 
alloantibodies in comparison to the studies 
in Malaysia (0.76% and 1.4%)[16]. 
However, the rate of alloimmunization in 
Chinese hospitalized population were 
reported differently from 0.21% to 0.5%, 
according to heterogeneity of the studied 
population [17, 18]. These different findings 
might be due to heterogeneity of the 
population and different screening and 
detecting methods. The relatively lower rate 
of alloantibodies in this study might be 
related to insensitive pre-transfusion tests or 
the lack of post transfusion screening tests, 
so the antibodies with short lifespan and 
low titer would disappear during the period 
of time after transfusion or due to their 
lower titer, they would merely be detected 
through tests with high sensitivity. It is 
known that LISS can detect the low titer 
antibodies better than Albumin; 
consequently, using Albumin as an 
enhancer in blood bank might lead to 
missing the low titer antibodies. The rate of 
alloantibodies might be underestimated as 
the result of the lag before antibody 
induction [4, 14] or due to a short life span 
of some antibodies, they could become 
undetectable within months after the 
formation [15]. The other factor that might 
impress the results of antibody detection 
was sensitivity of the testing methods. The 
lower rate of alloimmunization has shed 
light on the necessity of improvement in 
antibody screening tests in order to avoid 
hemolytic reactions. 
The higher prevalence of alloimmunization 
among female was seen in our study with 
male: female ratio of 1:5.2. The 
predomination of female in 
alloimmunization was seen in many other 
studies [19, 20] but not all studies confirm 
this fact [21]. The logic behind this result is 
that females are more exposed to 
alloantigens during the pregnancy. It should 
be considered that the most of the 
population of the present study were 
females and many of them were pregnant 
due to the active section of 
Gynecology/Obstetrics in the hospital. In 
earlier studies done in Iran, there was not 
any correlation between alloantibody 
formation and sex. The most frequent 
antibodies in this study’s population were 
anti-D, anti-E and anti-K respectively. It is 
noteworthy that although anti-D 
prophylaxis in obstetric women were 
performed in Iran, the most frequent 
antibody in females were anti-D and due to 
the predominant population of females than 
males in our study, anti-D is the most 
frequent antibody in this study similar to 
the other study done in Egypt [20] and 
different from some other studies with the 
predominance of anti-E [7, 18, 22]  and pre-
dominancy of anti-K [1, 4]. It can be 
postulated that this difference might be 
contributed to the study population or 
identification methods and enhancement 
methods. It is important to note that the high 
titer anti-D in the pregnant women in the 
present study would have been screened 
easier by the insensitive methods. The other 
reason of anti-D predominance in this study 
could be related to the transfusion of Rh-D 
positive platelet products for D-negative 
patients due to the lack of blood products in 
emergency cases. Anti-D formation might 
be stimulated due to residual RBCs or RBC-
drives micro particles in platelet blood 
products [23]. 
The other finding of this study was the 
association of age with alloimmunization. 
Results are comparable with the study by 
Zhuaning and colleagues [24] and 
Abdelrazik and colleagues [20] 
demonstrating the association of age with 
alloantibody detection. The highest 
frequency of alloimmunization were seen in 
patients aged 21-40, relatively, which is 
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similar to the study on hospitalized Chinese 
population [18]. However, in transfusion-
dependent patients such as major 
thalassemia, due to regular transfusions, the 
highest frequency of alloantibodies were 
seen in patients aged 1 to 17 [24]. In this 
study, females constitute the higher portion 
of patients and many of them who required 




     Alloantibody formation as an adverse 
effect of blood transfusion is still a concern 
of most clinicians. In this study on non-
transfusion dependent hospitalized patients 
in Iran, multi-variant factors affecting 
alloimmunization like age and sex and 
underlying disease were considered. 
However, due to retrospective design of the 
study, the other factors affecting 
alloimmunization, like the number of 
receiving units, leuko-reduced units and 
kinetics of antibody induction were not 
feasible for the purpose of the study. 
Further studies are required to assess the 
other predicators of alloimmunization. 
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